Allarity expands in-house lab to proteomics and cell line research, citing no cash-runway impact

Allarity Therapeutics, Inc.

In-house medical laboratory adds proteomics and cell line research, building on existing transcriptomics work and CLIA clinical testing services.
nCounter Pro instrument now also runs the nCounter Human Tumor Signaling Protein Panel, which measures approximately 300 protein targets.
Company says the expansion will not affect its current cash runway and may generate cost efficiencies by enabling more research in-house.
CEO Thomas Jensen: broader molecular insights support stenoparib (2X-121), a dual PARP and WNT pathway inhibitor in Phase 2 development.
New capabilities broaden the research services Allarity can offer to existing and prospective external partners.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.